Margarida Maia, PhD,  science writer—

Margarida is a biochemist (University of Porto, Portugal) with a PhD in biomedical sciences (VIB and KULeuven, Belgium). Her main interest is science communication. She is also passionate about design and the dialogue between art and science.

Articles by Margarida Maia

Groups ask lawmakers to preserve National ALS Registry funding

ALS groups are asking lawmakers to preserve federal funding for the National ALS Registry and National ALS Biorepository, the first and only comprehensive nationwide resource to collect and analyze data for better understanding amyotrophic lateral sclerosis (ALS). “A recently leaked draft memo from the U.S. Department of Health and…

RNS60 safe, well tolerated in EAP for advanced ALS

RNS60 was well tolerated when inhaled twice daily at home as part of an expanded access program (EAP), and it could be a safe option for people with advanced amyotrophic lateral sclerosis (ALS), a study suggested. “This EAP supports the safety and tolerability of RNS60,” researchers wrote in “…

AAN 2025: PrimeC reduces miRNAs linked to ALS progression

Neurosense Therapeutics’ oral therapy PrimeC significantly reduces blood levels of miRNAs — molecules involved in regulating gene activity — associated with disease progression and survival in people with amyotrophic lateral sclerosis (ALS). That’s according to six-month biomarker data from the Phase 2b PARADIGM clinical trial (NCT05357950), in which…

Cognixion seeks ALS patients for clinical trial of BCI headset

Cognixion is recruiting adults with amyotrophic lateral sclerosis (ALS) for a clinical trial testing ONE Axon-R, a wearable headset that combines augmented reality and brain-computer interface technology with an artificial intelligence (AI) application to facilitate communication. Launched early this year at a single site in the U.S., the…